Personalis (NASDAQ:PSNL) Upgraded at Wall Street Zen

Key Points

• Personalis (NASDAQ: PSNL) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, reflecting a more favorable outlook for the company's stock.
• Analysts have set varied price targets for Personalis, with a range from $6.00 by BTIG Research to $8.50 by HC Wainwright, indicating a consensus average target of $7.42.
• Institutional investment in Personalis has increased significantly, with American Century Companies raising its holdings by 33.9% and BNP Paribas Financial Markets increasing its holdings by an astonishing 53,126.7%.

Personalis (NASDAQ:PSNL - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

Other research analysts have also issued research reports about the company. BTIG Research set a $6.00 price objective on Personalis in a report on Wednesday, August 6th. HC Wainwright reissued a "buy" rating and set a $8.50 price objective on shares of Personalis in a report on Monday, September 8th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $7.42.

Personalis Price Performance

PSNL stock traded up $0.28 during mid-day trading on Friday, reaching $6.10. 1,454,507 shares of the company traded hands, compared to its average volume of 812,917. The company has a market capitalization of $540.95 million, a P/E ratio of -4.77 and a beta of 1.76. Personalis has a 52-week low of $2.83 and a 52-week high of $7.79. The company has a fifty day moving average price of $5.41 and a 200-day moving average price of $4.92.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%.The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts forecast that Personalis will post -1.4 EPS for the current year.

Institutional Trading of Personalis

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada lifted its position in Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock valued at $275,000 after purchasing an additional 2,395 shares during the last quarter. Howland Capital Management LLC lifted its position in Personalis by 0.9% in the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company's stock valued at $1,872,000 after purchasing an additional 2,500 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Personalis by 18.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company's stock valued at $62,000 after purchasing an additional 2,724 shares during the last quarter. Legal & General Group Plc bought a new stake in Personalis in the second quarter valued at approximately $30,000. Finally, Ameritas Investment Partners Inc. bought a new stake in Personalis in the second quarter valued at approximately $34,000. Institutional investors own 61.91% of the company's stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.